AgomAb Therapeutics (NASDAQ:AGMB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of AgomAb Therapeutics (NASDAQ:AGMB) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities research analysts have also recently issued reports about the company. Piper Sandler started coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target for the company. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. Finally, Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a research note on Wednesday, August 19th. They issued an “overweight” rating for the company. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Stock Down 3.9%

NASDAQ AGMB opened at $11.70 on Friday. The firm’s fifty day simple moving average is $13.32 and its two-hundred day simple moving average is $12.31. AgomAb Therapeutics has a 12-month low of $8.75 and a 12-month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. On average, analysts predict that AgomAb Therapeutics will post -1.76 earnings per share for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics N.V. (NASDAQ: AGMB) is a clinical-stage biopharmaceutical company developing medicines for diseases involving tissue damage, fibrosis and impaired regeneration. The company’s approach includes modulating biological pathways that influence tissue repair and remodeling, with the goal of addressing conditions with significant unmet medical needs.

AgomAb’s lead clinical program is AGMB-129, an oral, gut-restricted inhibitor of activin receptor-like kinase 5 (ALK5), a receptor involved in transforming growth factor beta signaling.